asco 2019: advanced stage disease highlights · slide 12 presented by luis paz -ares at 2019 asco...
Post on 06-Aug-2020
1 Views
Preview:
TRANSCRIPT
ASCO 2019:Advanced Stage Disease Highlights
Dr Tom Newsom-Davis BSc FRCP PhDConsultant Medical Oncologist, Chelsea & Westminster Hospital, London
Vice Chair, BTOG Steering Group
@tnewsomdavis
Disclosures
Support to attend educational conferences:Astra Zeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Otsuka, Roche, Takeda
Advisory and consultancy work: Amgen, Astra-Zeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Otsuka, Pfizer, Roche, Takeda
Speaker bureau:Astra-Zeneca, MSD, Roche
Abstract 9001
So where does gef + C fit in the current treatment algorithm?
Presented By Vanita Noronha at 2019 ASCO Annual Meeting
Abstract 9007
Abstract 9008
Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK) and Efficacy of AMG 510, a Novel Small Molecule KRASG12C Inhibitor, in Advanced Solid Tumors
Presented By Marwan Fakih at 2019 ASCO Annual Meeting
Abstract 3003
AMG 510 is a First in Class KRASG12C Inhibitor
Presented By Marwan Fakih at 2019 ASCO Annual Meeting
AMG 510 First in Human Study Design
Presented By Marwan Fakih at 2019 ASCO Annual Meeting
Patient Incidence of Common (>10%) and Serious Treatment Emergent Adverse Events (TEAE)
Presented By Marwan Fakih at 2019 ASCO Annual Meeting
NSCLC: Best Tumor Response* (n=10)
Presented By Marwan Fakih at 2019 ASCO Annual Meeting
Duration of Treatment by Tumor Types and Responses (n=29)
Presented By Marwan Fakih at 2019 ASCO Annual Meeting
Abstract 9013
Slide 1
Presented By Luis Paz-Ares at 2019 ASCO Annual Meeting
Abstract 8506
Slide 9
Presented By Luis Paz-Ares at 2019 ASCO Annual Meeting
Slide 12
Presented By Luis Paz-Ares at 2019 ASCO Annual Meeting
Slide 15
Presented By Luis Paz-Ares at 2019 ASCO Annual Meeting
Slide 16
Presented By Luis Paz-Ares at 2019 ASCO Annual Meeting
top related